Literature DB >> 11775897

[Evaluation of tumor necrosis factor-alpha and interleukin-6 levels in serum and peritoneal fluid of patients with endometriosis].

B Li1, F Jin, L Yang.   

Abstract

OBJECTIVES: To evaluate the levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) before and after conservative laparoscopic surgery in patients with endometriosis.
METHODS: The TNF-alpha and IL-6 levels in serum and peritoneal fluid of 20 endometriotic patients and 10 control patients were determined by radioimmunoassay.
RESULTS: Significant parallel relationship existed between the stage of endometriosis and the TNF-alpha and IL-6 levels in serum and peritoneal fluid in endometriosis patients (r values: serum: 0.80, 0.52; peritoneal fluid: 0.79, 0.49, P < 0.05). After clearance of endometriosis foci with laparoscopic conservative surgery, the TNF-alpha and IL-6 levels decreased significantly.
CONCLUSION: Measuring TNF-alpha and IL-6 level may have important value in postoperative follow-up, surveillance and evaluation of the effectiveness of surgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11775897

Source DB:  PubMed          Journal:  Zhonghua Fu Chan Ke Za Zhi        ISSN: 0529-567X


  3 in total

Review 1.  Inflammatory MicroRNAs and the Pathophysiology of Endometriosis and Atherosclerosis: Common Pathways and Future Directions Towards Elucidating the Relationship.

Authors:  Zubeen D Azari; Fatimah Aljubran; Warren B Nothnick
Journal:  Reprod Sci       Date:  2022-04-27       Impact factor: 2.924

Review 2.  Blood biomarkers for the non-invasive diagnosis of endometriosis.

Authors:  Vicki Nisenblat; Patrick M M Bossuyt; Rabia Shaikh; Cindy Farquhar; Vanessa Jordan; Carola S Scheffers; Ben Willem J Mol; Neil Johnson; M Louise Hull
Journal:  Cochrane Database Syst Rev       Date:  2016-05-01

Review 3.  Recent advances in the understanding of endometriosis: the role of inflammatory mediators in disease pathogenesis and treatment.

Authors:  Warren Nothnick; Zahraa Alali
Journal:  F1000Res       Date:  2016-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.